Sentinel Trust Co. LBA Sells 60,000 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Sentinel Trust Co. LBA lowered its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 19.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 255,000 shares of the company’s stock after selling 60,000 shares during the period. Sentinel Trust Co. LBA owned approximately 0.20% of Nautilus Biotechnology worth $428,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in NAUT. SG Americas Securities LLC grew its position in shares of Nautilus Biotechnology by 56.3% during the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after buying an additional 9,904 shares during the period. Palumbo Wealth Management LLC grew its holdings in Nautilus Biotechnology by 45.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after purchasing an additional 8,888 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Nautilus Biotechnology in the third quarter worth $67,000. China Universal Asset Management Co. Ltd. increased its stake in Nautilus Biotechnology by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after purchasing an additional 9,404 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in shares of Nautilus Biotechnology during the third quarter valued at about $87,000. 50.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, The Goldman Sachs Group lowered Nautilus Biotechnology from a “neutral” rating to a “sell” rating and decreased their target price for the company from $2.25 to $1.75 in a research report on Thursday, December 5th.

Nautilus Biotechnology Trading Down 18.2 %

NASDAQ NAUT opened at $1.17 on Friday. The company has a market cap of $146.91 million, a P/E ratio of -2.09 and a beta of 1.21. The company has a fifty day simple moving average of $1.73 and a 200 day simple moving average of $2.26. Nautilus Biotechnology, Inc. has a 12-month low of $1.10 and a 12-month high of $3.09.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.